Valuation: Exelixis, Inc.

Market Cap 14.05B 12.04B 11.28B 10.31B 19.45B 1,340B 19.64B 133B 51.82B 676B 52.77B 51.62B 2,239B P/E 2026 *
17.5x
P/E 2027 * 14.9x
Enterprise Value 13.31B 11.41B 10.69B 9.76B 18.42B 1,269B 18.6B 126B 49.07B 640B 49.98B 48.89B 2,120B EV / Sales 2026 *
5.22x
EV / Sales 2027 * 4.33x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 week+5.62%
Current month+4.60%
1 month-0.73%
3 months+11.81%
6 months+27.30%
Current year+27.03%
1 week 44.89
Extreme 44.89
48.24
1 month 43.2
Extreme 43.2
49.7
3 years 17.94
Extreme 17.935
50.29
5 years 13.88
Extreme 13.885
50.29
10 years 8.74
Extreme 8.735
50.29
Manager TitleAgeSince
Chief Executive Officer 65 21/07/2010
Director of Finance/CFO 58 14/07/2015
Chief Operating Officer 63 31/01/2016
Director TitleAgeSince
Director/Board Member 70 31/01/2004
Director/Board Member 82 31/07/2004
Chairman 77 31/12/1997
Change 5-day change 1-year change 3-year change Capi.($)
+3.16%+3.68%+47.99%+136.50% 13.52B
+3.31%-3.70%+61.03%+103.64% 69.06B
+1.74%+1.06%+49.02%+87.38% 63.06B
+1.09%+22.96%+8.55%-3.03% 28.34B
-0.07%-3.56%-3.45%+467.26% 27.07B
+0.67%+9.81%+61.25%+16.24% 25.45B
+3.98%+4.37%+39.47%-14.65% 19.69B
+1.02%+6.43%+269.42%+420.34% 19.19B
+2.67%+2.58%+10.58%+558.90% 15.95B
+3.98%+6.78%+49.66%+157.94% 13.52B
Average +2.04%+4.20%+59.35%+193.05% 31.26B
Weighted average by Cap. +2.06%+3.06%+55.79%+157.10%

Financials

2026 *2027 *
Net sales 2.55B 2.19B 2.05B 1.87B 3.53B 243B 3.57B 24.17B 9.41B 123B 9.58B 9.37B 406B 2.87B 2.46B 2.3B 2.11B 3.97B 274B 4.01B 27.19B 10.58B 138B 10.78B 10.54B 457B
Net income 821M 703M 659M 602M 1.14B 78.24B 1.15B 7.77B 3.03B 39.47B 3.08B 3.01B 131B 974M 835M 782M 715M 1.35B 92.88B 1.36B 9.23B 3.59B 46.86B 3.66B 3.58B 155B
Net Debt -744M -638M -598M -546M -1.03B -70.97B -1.04B -7.05B -2.74B -35.81B -2.8B -2.73B -119B -1.62B -1.39B -1.3B -1.19B -2.25B -155B -2.27B -15.37B -5.98B -78.05B -6.09B -5.96B -258B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
-
Date Price Change
25/08/26 €48.25 +3.16%
24/08/26 €46.77 +1.20%
21/08/26 €46.21 +1.09%
20/08/26 €45.71 -1.72%
19/08/26 €46.51 +1.82%
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
56.72USD
Average target price
53.00USD
Spread / Average Target
-6.56%

Quarterly revenue - Rate of surprise